Honokiol: A promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells

International Journal of Oral Science

Volumn 3, Issue 1, 2011, Pages 34-42

  Chen, Xirui ^a   Lu, Rui ^b   Dan, Hongxia ^b   Liao, Ga ^b   Zhou, Min ^b   Li, Xiaoyu ^b   Ji, Ning ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SICHUAN UNIVERSITY   (China)

Author keywords

anticancer; apoptosis; honokiol; oral squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; FLUOROURACIL; HERBACEOUS AGENT; HONOKIOL; LIGNAN; PLANT EXTRACT;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; MAGNOLIACEAE; MOUTH TUMOR; NICK END LABELING; PHYTOTHERAPY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUGS, CHINESE HERBAL; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; IN SITU NICK-END LABELING; LIGNANS; MAGNOLIA; MOUTH NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 79953772398     PISSN: 16742818     EISSN: 20493169     Source Type: Journal    
DOI: 10.4248/IJOS11014     Document Type: Article

References (34)

1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts & figures 2007. on World Wide Web http://www.cancer.org/acs/groups/content/@nho/documents/ document/globalfactsandfigures2007rev2p.pdf. accessed on 26/10/2010.
2. Qiu WL, Zheng JW. Development of oral maxillofacial oncology in China. Chin Med J (Engl) 2003; 116: 1567-1573.
3. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30.
4. Liou KT, Lin SM, Huang SS, Chih CL, Tsai SK. Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Med 2003; 69: 130-134.
5. Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis. Thromb Res 1988; 50: 757-765.
6. Lo YC, Teng CM, Chen CF, Chen CC, Hong CY. Magnolol and honokiol isolated from magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 1994; 47: 549-553.
7. Kuribara H, Kishi E, Hattori N, Yuzurihara M, Maruyama Y. Application of the elevated plus-maze test in mice for evaluation of the content of honokiol in water extracts of magnolia. Phytother Res 1999; 13: 593-596. (Pubitemid 29520937)
8. Hirano T, Gotoh M, Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci 1994; 55: 1061-1069.
9. Yang SE, Hsieh MT, Tsai TH, Hsu SL. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squa-mous lung cancer CH27 cells. Biochem Pharmacol 2002; 63: 1641-1651.
10. Bai X, Cerimele F, Ushio-Fukai M, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003; 278: 35501-35507. (Pubitemid 37102321)
11. 2+ mobilization in rat cortical neurons and human neuroblastoma SH-SY5Y cells. Eur J Pharmacol 2003; 474: 199-204. (Pubitemid 37281449)
12. Park EJ, Zhao YZ, Kim YH, Lee BH, Sohn DH. Honokiol induces apoptosis via cytochrome c release and caspase acti-vation in activated rat hepatic stellate cells in vitro. Planta Med 2005; 71: 82-84. (Pubitemid 40223358)
13. Hahm ER, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastomaretino- blastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther 2007; 6: 2686-2695. (Pubitemid 350058149)
14. Feng Y, He F, Zhang P, et al. Inhibitory effect of HMGN2 protein on human hepatitis B virus expression and replication in the HepG2.2.15 cell line. Antiviral Res 2009; 81: 277-282.
15. Luo H, Zhong Q, Chen LJ, et al. Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer. J Cancer Res Clin Oncol 2008; 134: 937-945.
16. Shen J, Huang C, Jiang L, et al. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 2007; 73: 1901-1909. (Pubitemid 46677907)
17. Wang T, Chen F, Chen Z, et al. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol 2004; 10: 2205-2208. (Pubitemid 39144968)
18. Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol 2001; 2: 545-550. (Pubitemid 33673405)
19. Wang Z, Jiang L, Huang C, et al. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics 2008; 7: 1639-1650.
20. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-422. (Pubitemid 29022420)
21. Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol 2000; 27: 25-33. (Pubitemid 30643362)
22. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus 5-Fu and carboplatin plus 5-Fu versus methotrexate in advanced squamous-cell carcinoma of the head and neck-a Southwest-oncology-group study. J Clin Oncol 1992; 10: 1245-1251.
23. Kaufmann SH, Vaux DL. Alterations in the apoptotic machi-nery and their potential role in anticancer drug resistance. Oncogene 2003; 22: 7414-7430. (Pubitemid 37487167)
24. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res 2002; 8: 2024-2034. (Pubitemid 34753570)
25. Malaguarnera L. Implications of apoptosis regulators in tumori-genesis. Cancer Metastasis Rev 2004; 23: 367-387.
26. Luqmani YA. Drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14: 35-48.
27. Chen F, Wang T, Wu YF, et al. Honokiol: a potent chemo-therapy candidate for human colorectal carcinoma. World J Gastroenterol 2004; 10: 3459-3463. (Pubitemid 39549546)
28. Hibasami H, Achiwa Y, Katsuzaki H, et al. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int J Mol Med 1998; 2: 671-673.
29. Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosar-coma HT-1080. Invasiveness in vitro. Planta Med 2001; 67: 705-708. (Pubitemid 33044474)
30. Li L, Han W, Gu Y, et al. Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore. Cancer Res 2007; 67: 4894-4903. (Pubitemid 46910198)
31. Tsai SK, Huang SS, and Hong CY. Myocardial protective effect of honokiol: an active component in magnolia officinalis. Planta Med 1996; 62: 503-506. (Pubitemid 27006682)
32. Chiu JH, Ho CT, Wei YH, Lui WY, Hong CY. In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury. Life Sci 1997; 61: 1961-1971.
33. Ishitsuka K, Hideshima T, Hamasaki M, et al. Honokiol overcomes conventional drug resistance in human multiple-myeloma by induction of caspase-dependent and-independent apoptosis. Blood 2005; 106: 1794-1800. (Pubitemid 41208596)
34. Garcia A, Zheng Y, Zhao C, et al. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res 2008; 14: 4267-4274.